The thorough analysis of >4582 tumors from 90 different tumor types demonstrated in this study, that the cross-reactivities detected for our two CTLA-4 antibodies hindered the quantitation of CTLA-4+ lymphocytes in only few tumor entities. This evidence concerns the gene CTLA4 and neoplasm.